Raymond James Financial
CTMX icon

Raymond James Financial’s CytomX Therapeutics CTMX Stock Holding History

Raymond James Financial’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.79M Buy
380,160
+63,189
+20% +$321K ﹤0.01% 3441
2025
Q4 		$1.35M Buy
316,971
+23,411
+8% +$88.9K ﹤0.01% 3582
2025
Q3 		$936K Buy
293,560
+10,000
+4% +$22.5K ﹤0.01% 3722
2025
Q2 		$644K Buy
+283,560
New +$457K ﹤0.01% 3846

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Raymond James Financial's CTMX Position: Q1 2026 in Review

Raymond James Financial increased its CytomX Therapeutics (CTMX) stake by 20% in Q1 2026, buying an estimated $321K and bringing the position to 380,160 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #3441.

Raymond James Financial first reported a position in CTMX in Q2 2025 and has held it in 4 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Raymond James Financial held 380,160 shares of CytomX Therapeutics worth $1.79M as of Q1 2026.
  • Raymond James Financial bought 63,189 CytomX Therapeutics shares in Q1 2026, an estimated $321K.
  • CytomX Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3441 holding.
  • Raymond James Financial first reported a position in CytomX Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.